相关临床试验
3032
420 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
终止
67
2.2%
招募中
560
18.5%
暂停
4
0.1%
Available
1
0.0%
撤回
37
1.2%
进行中（未招募）
123
4.1%
Unknown
497
16.4%
已完成
1446
47.7%
Enrolling By Invitation
15
0.5%
尚未招募
282
9.3%
暂无批准数据
- A UNIST research center has been selected for the Korean ARPA-H Project to develop external blood purification technology that filters metastasis-promoting substances from the bloodstream to block cancer spread. - The center will receive about 8 billion won ($5.8 million) over four and a half years, with Professor Kang Joo-heon serving as lead researcher. - The approach builds on a sepsis blood purification platform and will initially target colorectal cancer patients at risk of recurrence or metastasis, with plans to extend to other metastatic cancers. - A collaborative network including Yonsei University College of Medicine, Seoul National University Bundang Hospital, Artblood, Sebica, Evertry, and the Korea Testing & Research Institute will support clinical application and commercialization.
- Hyundai Bioscience has dosed the first prostate cancer patient with Penitrium in a Phase 1 trial testing whether the drug restores hormone therapy efficacy. - Penitrium is an oral niclosamide formulation designed to dismantle physical defense barriers in the tumor microenvironment that reduce drug delivery to sub-lethal levels. - The FDA approved an investigational new drug application for a US Phase 2a trial combining Penitrium with standard care in relapsed or refractory advanced solid tumors. - Organoid data showed Penitrium plus daraxonrasib cut ovarian cancer cell viability to 12.8% versus 67.7% with daraxonrasib alone in CAF co-culture.
- A large-scale observational study found semaglutide use was associated with a 56% lower risk of adult-onset seizures compared to other glucose-lowering agents in type 2 diabetes patients. - The seizure risk reduction could not be explained by improvements in blood glucose or body weight alone, suggesting direct brain-protective mechanisms. - Other GLP-1 receptor agonists did not show a comparable seizure-preventive effect, pointing to semaglutide's unique pharmacological properties including partial brain penetration. - Researchers emphasize that long-term follow-up studies and randomized clinical trials are needed to confirm the preventive effect before clinical application.
- Seoul National University Hospital, in collaboration with Samsung Medical Center, has been testing personalized radiopharmaceutical therapy for children with treatment-resistant solid tumors since February 2024. - The experimental treatment acts like a "radiation missile," combining a radioactive isotope with a molecule that binds to cancer cells to deliver radiation directly to tumors. - Since 2024, nine treatment rounds have been administered to five children with returned or treatment-resistant solid tumors, with no disease progression and stable patient conditions reported. - The Lee Kun-Hee Foundation-funded initiative covers treatment costs, sparing families nearly 10 million won per session, and establishes a pathway for bringing this therapy to pediatric patients in Korea.
- Penetrium Bioscience announced new scientific evidence demonstrating the cellular mechanism behind the 137-year-old "Seed & Soil" theory, showing how tumor microenvironments limit targeted therapy efficacy. - The company's novel approach targets pathological macrophages and cancer-associated fibroblasts to disrupt the tumor's protective ecosystem, enabling co-administered therapies to achieve lethal concentrations. - Independent validation studies by Seoul National University Hospital and KAIST confirmed the mechanism's consistency with RNA sequencing data from pancreatic cancer organoids. - Penetrium positions its platform as a combination therapy partner to restore efficacy to existing targeted therapies constrained by resistance mechanisms.
- Korean researchers at Seoul National University Bundang Hospital developed SC Fill paste, an injectable tissue filler made from processed human skin that could offer a less invasive alternative to traditional breast reconstruction methods. - The paste demonstrated superior blood vessel formation and cell recruitment compared to commercial products in six-month rat studies, with inflammatory markers declining over time. - The injectable format allows surgeons to adapt the material to irregular defect shapes without additional incisions, potentially reducing scarring and recovery times for breast cancer patients. - While promising, the research remains in early animal testing stages and requires further studies before potential human clinical trials.
- GC Biopharma's BARYTHRAX, the world's first recombinant anthrax vaccine, demonstrated protective antibody levels exceeding pre-defined thresholds in a Phase 2 trial with 240 participants. - The randomized, double-blind, placebo-controlled study showed the vaccine elicited robust immunogenicity with only mild, temporary adverse events and no serious safety concerns. - BARYTHRAX represents Korea's first domestically developed recombinant anthrax vaccine, offering advantages over traditional live attenuated bacterial vaccines including improved safety and rapid mass production capability. - The positive Phase 2 results, published in the international journal Vaccine, mark a significant milestone for biodefense preparedness and vaccine localization efforts in South Korea.
- A randomized clinical trial of 400 children under age 2 found no meaningful differences in IQ, behavior, or language development at 30 months between those receiving sevoflurane alone versus a balanced anesthesia regimen. - The study provides reassurance following 2017 FDA warnings about anesthesia risks in young children, adding to evidence that brief, single anesthetic exposures are unlikely to cause clinically significant neurodevelopmental impairment. - Results from Seoul National University Hospital showed that reducing sevoflurane exposure through balanced anesthesia effectively lowered anesthetic requirements but provided no measurable developmental advantages. - Final results including long-term follow-ups at age 5 years with full-scale IQ assessments are still pending to confirm these preliminary findings.
- MedPacto's Vactosertib demonstrated a 36.4% objective response rate in Phase 1 osteosarcoma trials, including one complete remission case, representing more than three times the efficacy of existing treatments. - The company has expanded its Phase 2 clinical trial to six major Korean hospitals and received compassionate use requests from prominent US medical institutions including Johns Hopkins and Stanford. - Vactosertib has received orphan drug designation in the US and Europe, along with FDA Fast Track designation, with Breakthrough Therapy designation discussions ongoing.
- Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021. - Korea University will conduct the first large-scale plasma proteomics study of its kind, analyzing 20,000 samples from cancer patients and healthy controls to develop AI-driven diagnostics for early-onset cancers in young adults. - The three-year study, funded by Korea's K-Health MIRAE initiative, aims to identify novel blood-based biomarkers for cancer detection in patients in their 20s and 30s using samples from leading Korean cancer institutions. - The new workflow identifies up to 10 times more proteins than conventional mass spectrometry methods and completes 80-sample batches in under 5 hours of automated runtime.
